A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Clinical trial NCT04077723 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04077723
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-13
- Primary completion
- 2027-03-31
- Enrollment
- 498
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.